Pharmosa Biopharm Inc. (6875.TWO)
TWD 53.2
(-1.48%)
TWD 53.2
(-1.48%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | 42.42 Million | -258.3 Million | -237.5 Million | -181.45 Million | - |
| Net Income | 8.45 Million | -266.5 Million | -256.47 Million | -181.69 Million | - |
| Depreciation & Amortization | 23.32 Million | 12.7 Million | 11.8 Million | 10.61 Million | - |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | 868 Thousand | 593 Thousand | 15.03 Million | 4 Million | - |
| Change in working capital | 15.28 Million | -1.15 Million | -7.18 Million | -9.74 Million | - |
| Other non-cash items | -6.66 Million | 149 Thousand | 1.11 Million | 3.82 Million | - |
| Investing Cash Flow | -93.84 Million | -10.17 Million | 4.75 Million | -5.06 Million | - |
| Investments in PPE | -81.46 Million | -10.18 Million | -3.24 Million | -7.05 Million | - |
| Acquisitions | - | - | - | - | 30.04 Million |
| Investment purchases | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - |
| Other Investing Activities | -12.37 Million | 18 Thousand | 8 Million | 1.98 Million | - |
| Financing Cash Flow | 352.96 Million | 479.52 Million | 279.68 Million | 596.8 Million | - |
| Debt repayment | -3.52 Million | -8.41 Million | -80.25 Million | -21.78 Million | - |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 364.45 Million | 495.41 Million | 367.02 Million | 637.29 Million | - |
| Other Financing Activities | 2.72 Million | 495.41 Million | 306.02 Million | -12 Million | 12 Million |
| Accounts receivables | -1.18 Million | 32 Thousand | -142 Thousand | -149 Thousand | - |
| Accounts payables | 585 Thousand | - | - | - | - |
| Inventory | -21.9 Million | - | - | - | - |
| Other working capital | 37.78 Million | -1.18 Million | -9.04 Million | -8.82 Million | - |
| Cash at beginning of period | 672.51 Million | 461.46 Million | 414.53 Million | 4.24 Million | - |
| Cash at end of period | 974.05 Million | 672.51 Million | 461.46 Million | 414.53 Million | - |
| Capital Expenditure | -81.46 Million | -10.18 Million | -3.24 Million | -7.05 Million | - |
| Effect of forex changes on cash | 1000.00 | 5000.00 | - | - | - |
| Net cash flow / Change in cash | 301.54 Million | 211.05 Million | 46.92 Million | 410.29 Million | - |
| Free Cash Flow | -39.04 Million | -268.49 Million | -240.75 Million | -188.5 Million | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -58.6 Million | -52.92 Million | -91.35 Million | 8.45 Million | 230.65 Million | -67.29 Million |
| Depreciation & Amortization | 5.9 Million | 5.74 Million | 7.94 Million | 23.32 Million | 7.18 Million | 4.83 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 16 Thousand | 3.53 Million | -65 Thousand | 868 Thousand | 92 Thousand | 1.23 Million |
| Change in working capital | -10.73 Million | 9.09 Million | 17.62 Million | 15.28 Million | -8.27 Million | -12.78 Million |
| Other non-cash items | -7.29 Million | -4.71 Million | -5.26 Million | -6.66 Million | -470 Thousand | -1.02 Million |
| Investing Cash Flow | -42.24 Million | -27.88 Million | -86.79 Million | -93.84 Million | -3.17 Million | -2.86 Million |
| Investments in PPE | -41.91 Million | -27.86 Million | -80.36 Million | -81.46 Million | -90 Thousand | -1000.00 |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -335 Thousand | -19 Thousand | -6.43 Million | -12.37 Million | -3.08 Million | - |
| Financing Cash Flow | -6.46 Million | 956.21 Million | -6.01 Million | 352.96 Million | 359.4 Million | -2.51 Million |
| Debt repayment | -2.13 Million | -312 Thousand | -727 Thousand | -3.52 Million | -934 Thousand | -931 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 962.13 Million | - | 364.45 Million | 362.2 Million | - |
| Other Financing Activities | -4.32 Million | 962.13 Million | - | 2.72 Million | 362.2 Million | - |
| Accounts receivables | -602 Thousand | 357 Thousand | 29.92 Million | -1.18 Million | -31.39 Million | - |
| Accounts payables | -464 Thousand | - | - | - | - | - |
| Inventory | 2.82 Million | -16.95 Million | -5.46 Million | -21.9 Million | -16.44 Million | - |
| Other working capital | -8.29 Million | -3.09 Million | 1.07 Million | 37.78 Million | 29.4 Million | - |
| Cash at beginning of period | 1.86 Billion | 974.05 Million | 1.13 Billion | 672.51 Million | 550.05 Million | 631.22 Million |
| Cash at end of period | 1.74 Billion | 1.86 Billion | 974.05 Million | 974.05 Million | 1.13 Billion | 550.05 Million |
| Capital Expenditure | -41.91 Million | -27.86 Million | -80.36 Million | -81.46 Million | -90 Thousand | -1000.00 |
| Effect of forex changes on cash | 8000.00 | - | -1000.00 | 1000.00 | 2000.00 | - |
| Net cash flow / Change in cash | -115.54 Million | 891.31 Million | -160.28 Million | 301.54 Million | 584.28 Million | -81.16 Million |
| Free Cash Flow | -108.75 Million | -64.87 Million | -147.83 Million | -39.04 Million | 227.97 Million | -75.78 Million |
3131
2062
4106
WISE
5272
9845